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Transient receptor potential vanilloid 6 (TRPV6) functions in tetramer form for calcium transport.
Until now, TRPV6 has not been linked with skeletal development disorders. An infant with ante-
natal onset thoracic insufficiency required significant ventilatory support. Skeletal survey
showed generalized marked undermineralization, hypoplastic fractured ribs, metaphyseal frac-
tures, and extensive periosteal reaction along femoral, tibial, and humeral diaphyses. Parathyroid
hormone (PTH) elevation (53.4–101 pmol/L) initially suggested PTH signaling disorders.
Progressively, biochemical normalization with radiological mineralization suggested recovery
from in utero pathophysiology. Genomic testing was undertaken and in silico protein modeling
of variants. No abnormalities in antenatal CGH array or UPD14 testing. Postnatal molecular
genetic analysis found no causative variants in CASR, GNA11, APS21, or a 336 gene skeletal dys-
plasia panel investigated by whole exome sequencing. Trio exome analysis identified compound
heterozygous TRPV6 likely pathogenic variants: novel maternally inherited missense variant,
c.1978G > C p.(Gly660Arg), and paternally inherited nonsense variant, c.1528C > T p.(Arg510-
Ter), confirming recessive inheritance. p.(Gly660Arg) generates a large side chain protruding
from the C-terminal hook into the interface with the adjacent TRPV6 subunit. In silico protein
modeling suggests steric clashes between interface residues, decreased C-terminal hook, and
TRPV6 tetramer stability. The p.(Gly660Arg) variant is predicted to result in profound loss of
TRPV6 activity. This first case of a novel dysplasia features severe but improving perinatal
abnormalities. The TRPV6 compound heterozygous variants appear likely to interfere with feto-
placental calcium transfer crucial for in utero skeletal development. Astute clinical interpretation
of evolving perinatal abnormalities remains valuable in complex calcium and bone pathophysiol-
ogy and informs exome sequencing interpretation.
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1 | INTRODUCTION
Recent advances in molecular genetics have facilitated an expansion
and refinement of skeletal dysplasias and metabolic bone conditions
diagnosed perinatally (Bonafe et al., 2015).
Fetal skeleton mineralization depends upon fetal plasma calcium
sourced through active placental transfer, long attributed to parathy-
roid hormone (PTH) and PTH-related peptide activity (Simmonds &
Kovacs, 2010). Recently identified additional factors include calbindin
(intracellular calcium binding protein), sodium/calcium exchangers
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(Koo et al., 2012), and TRPV6 (sixth member of the transient receptor
potential vanilloid subfamily) (Montell, Birnbaumer, & Flockerzi, 2002).
TRPV6 is relevant to calcium absorption (Fecher-Trost,
Wissenbach, & Weissgerber, 2017). TRPV6 gene location and expres-
sion varies across species; in humans, TRPV6 is situated on chromo-
some 7q33-q34 and is expressed in prostate, placenta, epididymis,
and exocrine pancreas (Wissenbach et al., 2001). Research has
focused on the potential contribution of TRPV6 overexpression in
prostate and breast cancer. Fewer reports address underexpression:
the trpv6−/− knockout mouse has hypofertility due to altered calcium
homeostasis in the epididymis and in humans reduced placental
expression is associated with preeclampsia (Haché et al., 2011). Until
now, TRPV6 has not been linked with disorders of bone mineralization
or skeletal dysplasia. We describe a patient with this phenotype and
compound heterozygote TRPV6 variants occurring in trans, illustrating
how astute clinical interpretation of evolving perinatal calcium and
bone pathophysiology informed the interpretation of trio exome
sequencing.
2 | CASE
A term female infant required significant and prolonged ventilatory
support from birth due to severe thoracic insufficiency, accompanied
by skeletal and biochemical abnormalities. Management included diffi-
cult discussions around survival. Therefore, identifying the underlying
diagnosis in this neonate with rare bone disease was invaluable to bet-
ter inform prognosis.
Antenatal abnormalities were noted early in pregnancy on the
20/40 gestation scan: small chest, unusual rib configuration, short but
straight long bones, and no fractures identified. Pregnancy was com-
plicated by severe and reaccumulating polyhydramnios which required
three amniotic fluid drainage procedures from 27/40 gestation. There
was no preeclampsia. Parents were counseled regarding the severe
phenotype of the potentially lethal skeletal dysplasia, with no clear
diagnosis.
Elective induction of labor at 391/40, emergency cesarean
section delivery due to fetal distress, birth weight 3.6 kg, Apgars
31,65,810, and endotracheal intubation and ventilation were required
in the delivery room. Clinical features included a marked bell-shaped
chest, otherwise normal proportions, no dysmorphic features and neu-
rologically normal (Figure 1a). Ventilatory requirement persisted; trial
of extubation failed Days 4 and 15 and conventional mechanical ven-
tilation was required with maximum pressures of 30 cm H20 and
FiO2 0.6. Morphine infusion and paralysis were required for pain
attributed to underlying fractures.
The skeletal survey showed widespread undermineralization, short,
fractured ribs, metaphyseal irregularities with corner fractures, and peri-
osteal reaction along diaphyses of the long bones (Figure 1b–i).
Early biochemical abnormalities featured markedly elevated PTH
53.4 rising to 101 pmol/L (normal 1.1–6.9 pmol/L), normocalcemia
FIGURE 1 Clinical and radiological findings. (a) The bell-shaped chest was associated with respiratory distress. (b–i) The skeletal survey at the age
of 2 weeks showed generalized undermineralization, short, thin, and fractured ribs, absence of Wormian bones and normal vertebrae. The long
bones showed a similar pattern of metaphyseal irregularities with corner fractures and periosteal reaction most obvious along the diaphyses of
femora, tibiae and humeri. (j, k) Radiographs of chest and femur at the age of 10 weeks, showed broader, longer ribs, partial resolution of the
metaphyseal lesions, and improved bone mineralization [Color figure can be viewed at wileyonlinelibrary.com]
BURREN ET AL. 1951
corrected calcium 2.43 mmol/L, normophosphatemia 1.4 mmol/L, nor-
mal Alkaline Phosphatase (ALP) 289 IU/L, normal urinary calcium/creat-
inine ratio 1.05, and vitamin D insufficiency 29 nmol/L. Parental
biochemistry was normal.
Neonatal severe hyperparathyroidism (NSHPT) was considered,
based on marked PTH elevation and periosteal abnormalities, despite
the absence of hypercalcemia; pamidronate single dose Day 16 then
daily cinacalcet (calcimimetic) were used preemptively to avoid
anticipated severe hypercalcemia (Fisher, Cabrera, & Imel, 2015).
PTH normalized, serum calcium did not rise, including after cinacalcet
cessation. Transient mild hypocalcemia and hypophosphatemia
occurred at weeks 3–4.
At the age of 6 weeks, X-rays showed improved rib mineralization
and width and there was partial resolution of long bone periosteal
abnormalities (Figure 1j,k). Ongoing metabolic bone strategy was oral
calcium provision as substrate to facilitate bone mineralization and
routine vitamin D supplementation (400 IU/day). The ventilatory
requirement remained significant but sufficiently improved, with a
decision to commence long-term ventilation through a tracheostomy
from 8 weeks.
Throughout 2–4 months of age, skeletal mineralization improved
and ventilation stabilized on bi-level pressures of 16/6 without addi-
tional oxygen. Developmental progress was normal. There was a
degree of feed volume intolerance attributed to thorax and abdomen
size and no other abnormalities identified. Preparation commenced
toward transfer and home ventilation, envisaged for approximately
12 months.
Unexpectedly at 4 months, she developed sudden and marked
abdominal distension followed by cardiac arrest, profound, and
prolonged lactic acidosis. Emergency laparotomy identified volvulus
and ischemic bowel. Neurological status postarrest was extremely
poor, Magnetic Resonance Imaging (MRI) brain demonstrated global
ischemic injury and ultimately care was withdrawn. Limited postmor-
tem confirmed the presence of volvulus, the absence of underlying
malrotation, or other gastrointestinal tract configuration abnormalities
and mildly enlarged heart with a degree of fiber disarray, although
postmortem did not establish a definitive cause of death beyond the
presence of volvulus.
3 | METHODS
Editorial Policies and Ethical Considerations: written consent was
obtained from the patient’s parents for publication of clinical photo-
graphs and clinical information.
Whole exome sequencing was performed with DNA samples
from the patient and her unaffected parents using the Agilent SureSe-
lect All Exon v6 system, with sequencing on an Illumina NextSeq 500.
Likely causative variants were confirmed by Sanger sequencing.
4 | RESULTS
Antenatal genetic tests were normal including Array comparative
genomic hybridization (aCGH) and investigation for paternal UPD14
(Kagami–Ogata syndrome), undertaken in view of the thoracic
appearance.
Postnatally, careful clinical assessment suggested skeletal devel-
opmental pathology was the likely primary mechanism resulting in
small lungs instead of primary lung pathology (pulmonary hypoplasia).
Biochemical abnormalities were not typical of Jeune asphyxiating
thoracic dystrophy (in which constrained bone growth would continue
postnatally). In contrast, correcting metabolic bone abnormalities
could improve bone development aiding rib growth to facilitate lung
function.
Initial postnatal genetic testing adopted a targeted single gene
approach to explore NSHPT; the initial working diagnosis supported
by periosteal changes and marked PTH elevation, although absent
hypercalcemia was contradictory. Sanger sequencing of the CASR
gene did not identify biallelic inactivating variants. We performed
whole exome sequencing in the proband to test for variants in the
GNA11 and AP2S1 genes (less common causes of NSHPT) and also
analyzed GNPTG as hyperparathyroidism and periosteal changes also
occur in I-cell disease (mucolipidosis Type II). We then applied a
broader strategy to explore other causes of bone fragility or skeletal
dysplasias using the PanelApp Skeletal Dysplasia Panel Version 1.66,
which includes 336 “green” genes (PanelApp skeletal dysplasia panel
version 1.66, 2016). No likely causative variants were found through
these gene-focused approaches, excluding a diagnosis of a known
form of skeletal dysplasia.
This extensive negative genetic testing, alongside postnatal clini-
cal, biochemical, and radiological changes prompted revision of the
intrinsic PTH abnormality hypothesis. Normalized PTH and progres-
sively improved skeletal mineralization suggested the PTH elevation
had been reactive to in utero calcium deficiency which progressively
resolved in the postnatal environment. The in utero calcium deficiency
was not felt to be due to maternal factors (normal biochemistry,
health and pregnancy vitamin supplementation). Instead, an intrinsic
defect in placental calcium transfer was postulated, prompting direct
exploration of the candidate genes TRPV6, CABP9K, and VDR. We
sequenced the unaffected parents and performed a gene-agnostic trio
analysis to identify very rare variants (MAF < 0.0001) compatible with
autosomal recessive or de novo inheritance. This identified two genes
with possible compound heterozygous single nucleotide variants
(SNVs) or indels and one gene with a de novo variant. These included
compound heterozygous TRPV6 variants (NM_018646.5); a novel mis-
sense variant, p.(Gly660Arg), and a rare nonsense variant, p.(Arg510-
Ter) classified according to the ACMG guidelines (Richards et al.,
2015) as likely pathogenic (missense: PM2_moderate, PM3_moderate,
PP3_supporting, PP4_supporting and nonsense: PVS1_very strong,
PM2_moderate). The p.(Arg510Ter) variant lies in exon 11 of 15, and
is assumed to induce nonsense-mediated decay. Glycine 660 lies
within the C-terminal hook region in the intracellular “skirt” of TRPV6
(Saotome, Singh, Yelshanskaya, & Sobolevsky, 2016). The C-terminal
hook packs against the N-terminal helix of the neighboring subunit,
forming an interface at each corner of the skirt (Figure 2a,b). To ana-
lyses the effect of the p.(Gly660Arg) substitution, in silico mutagene-
sis was performed using the Fold X modeling suite (Schymkowitz
et al., 2005) to introduce the variant into recently published structures
of TRPV6 in its open and closed forms (PDB identifiers 6bo8 and
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6boa, respectively, [McGoldrick et al., 2017]). In the predicted struc-
ture of the open form of the variant protein, the novel arginine side
chain protrudes into the interface between the C-terminal hook and
the N-terminal helix of the neighboring subunit, resulting in displace-
ment of a number of side chains which contribute both to the inter-
face and the stability of the loop forming the C-terminal hook
(Figure 2c,d). The p.(Gly660Arg) variant also resulted in steric clashes
between residues at the interface, and similar observations were
made for the closed form of the tetramer (data not shown). The struc-
ture of the hook is likely stabilized by a hydrophobic core formed by
nonpolar side chains, particularly Leu665, Ile658, and Phe670; the
introduction of the large, basic arginine side chain disrupts this envi-
ronment (Figure 3) and is expected to be energetically unfavorable.
Indeed, thermodynamic analysis of the tetramer using FoldX indicated
an increase in free energy (i.e., decrease in stability) of the open and
closed forms of 73.8 and 61.6 kcal/mol, respectively. Increases in free
energy >3 kcal/mol are generally regarded as highly destabilizing to
protein structure (Tokuriki & Tawfik, 2009), suggesting that the p.
(Gly660Arg) substitution is likely to cause loss of stability at the oligo-
merization interface and/or reduced formation of the functional tetra-
mer. This may also lead to reduced levels of TRPV6 protein as a result
of increased turnover of unstable or misfolded protein. Thus, in com-
bination with the p.(Arg510Ter) allele, the p.(Gly660Arg) variant is
predicted to result in a profound loss of TRPV6 activity.
5 | DISCUSSION
This case adds significantly to understanding of TRPV6 function in
humans. We hypothesize that structural/quantitative alterations in
TRPV6 in our patient reduced placental calcium transfer and resulted
in severely compromised in utero skeletal development and
FIGURE 2 Location of Gly660 and effect of p.(Gly660Arg) substitution. (a) Structure of the human TRPV6 tetramer in open form (PDB id 6bo8);
chains A–D are colored cyan, yellow, gray, and pink respectively; atoms of Gly660 are shown in all subunits as spheres colored by atom type
(white, carbon; blue, nitrogen; red, oxygen), and are labeled for subunits A and D. The complex is oriented to show view in the plane of the
membrane, represented by the gray bar, with the cytoplasmic region at the top. (b) As A, but rotated to show the view from the cytoplasm; the
ion channel lies at the center of the tetramer. (c) Detail of the interface between the C-terminal hook of subunit A (cyan) and the N-terminal helix
of subunit B (yellow); the position of the Gly660 backbone is indicated, and side chains shown in stick format, colored by atom type, for other
relevant residues; residues from subunits A and B are labeled in black or blue font, respectively. (d) As A, but showing detail of the p.(Gly660Arg)
variant. Variant details: missense is c.1978G > C and nonsense is c.1528C > T. Genomic coordinates Chr7(GRCh37):g.142570162C > G and
Chr7(GRCh37):g.142572288G > A) [Color figure can be viewed at wileyonlinelibrary.com]
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mineralization causing life-threatening thoracic insufficiency and mor-
bidity from postnatal fractures. Initial differential diagnoses to con-
sider include skeletal dysplasias characterized by poor skeletal
mineralization including osteogenesis imperfecta, hypophosphatasia,
mucolipidosis Type II, and NSHPT. The unusual clues in this case were
in the initial biochemical abnormalities, generally absent in skeletal
dysplasias, and their progressive postnatal resolution and bone healing
away from the in utero environment.
Finding the precise diagnosis in the patient was fundamental to
inform clinical decisions. A hypothesis driven approach to genetic
tests contributed first in excluding an unusual presentation of a rare
disease (some features suggested NSHPT but severity causing antena-
tal abnormalities has not been reported) and ongoing hypothesis
development complemented a gene-agnostic trio exome sequence
analysis.
Identification of compound heterozygous TRPV6 variants in this
patient coincides with new information on how TRPV6 operates for
calcium transfer. TRPV6 crystal structure has been recently described
(McGoldrick et al., 2017; Saotome et al., 2016). The gene changes in
our patient lie at the tetrameric interface crucial for calcium channel
function (McGoldrick et al., 2017) and are predicted to destabilize the
protein complex resulting in loss of calcium transport.
Although trpv6 is expressed in many mouse tissues, including
intestine, expression in humans appears restricted to placenta, exo-
crine pancreas, and some exocrine glands (Fecher-Trost et al., 2017).
Our case showed effects of compromised placental calcium transfer,
but did not demonstrate any exocrine pancreatic dysfunction features
such as intestinal malabsorption. The absence of preeclampsia does
not reinforce the hypothesis of TRPV6 dysfunction in preeclampsia
(Haché et al., 2011). Our case showed normal intestinal calcium trans-
fer during early infancy; although oral calcium supplementation was
briefly required to compensate for skeletal calcium deficiency, ongo-
ing normal milk calcium content achieved normocalcemia.
The TRPV gene family has previously been implicated in skeletal
dysplasia: mutations in the TRPV4 gene are associated with skeletal
dysplasia, arthritis-like, and neurological phenotypes including spondy-
lometaphyseal dysplasia Kozlowski type, brachyolmia Type 3, metatro-
pic dysplasia, spondyloepiphyseal dysplasia Maroteaux type, familial
digital arthropathy-brachydactyly, Charcot–Marie–Tooth disease Type
2C, congenital distal spinal muscular atrophy, and scapuloperoneal spi-
nal muscular atrophy (Krakow et al., 2009; Lamandé et al., 2014;
Zimon et al., 2010). Severe perinatal skeletal dysplasia has not been
reported in association with TRPV6. Our case has intriguing similarities
to severe antenatal-onset Caffey disease including polyhydramnios,
hyperostosis, periosteal reaction, and progressive resolution of bony
lesions over time (Schweiger et al., 2003), although we did not
observe soft tissue swellings or fever. Antenatal Caffey disease is very
rare and although heterozygote COL1A1 mutations have been identi-
fied in some cases (Gensure et al., 2005), genetic heterogeneity seems
likely and TRPV6 may be a candidate worth investigation in unsolved
cases.
Combined clinical and genetic expertise achieved diagnostic
precision for this case and contributes to understanding of TRPV6 in
human disease.
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